Successful treatment of steroid-refractory gastrointestinal GVHD with ruxolitinib in a patient after autologous stem cell transplantation: a case report
- 26.09.2025
- Case Report
- Verfasst von
- Duha Yahya
- Mona Ayran
- Ferhat Özden
- Amir Hossein Abedi
- Sureyya Yiğit Kaya
- Hüseyin Saffet Beköz
- Aslı Çakır
- Senem Maral
- Leylagül Kaynar
- Erschienen in
- International Journal of Hematology | Ausgabe 6/2025
Abstract
Introduction
Graft-versus-host disease (GVHD) is a serious immune reaction that usually occurs after allogenic stem cell transplants and can affect organs, such as skin, gastrointestinal (GI) system, and liver. The development of GVHD after autologous stem cell transplantation (auto-SCT) is rarely observed and only a few cases have been reported in the literature.
Case presentation
A 21-year-old patient who underwent auto-SCT for neurofibromatosis type 1 developed severe GI-GVHD confirmed by histopathology. She responded inadequately to systemic corticosteroids, indicating steroid-refractory disease. Subsequent addition of the JAK1/2 inhibitor ruxolitinib resulted in rapid clinical improvement.
Conclusion
This clinical case scenario suggests that ruxolitinib could be a treatment option in rare cases of GVHD following auto-SCT.
Anzeige
- Titel
- Successful treatment of steroid-refractory gastrointestinal GVHD with ruxolitinib in a patient after autologous stem cell transplantation: a case report
- Verfasst von
-
Duha Yahya
Mona Ayran
Ferhat Özden
Amir Hossein Abedi
Sureyya Yiğit Kaya
Hüseyin Saffet Beköz
Aslı Çakır
Senem Maral
Leylagül Kaynar
- Publikationsdatum
- 26.09.2025
- Verlag
- Springer Nature Singapore
- Erschienen in
-
International Journal of Hematology / Ausgabe 6/2025
Print ISSN: 0925-5710
Elektronische ISSN: 1865-3774 - DOI
- https://doi.org/10.1007/s12185-025-04073-2
Dieser Inhalt ist nur sichtbar, wenn du eingeloggt bist und die entsprechende Berechtigung hast.